A large, long-term study found a 97% event-free survival rate at 18 months.
Two recent studies have found that signaling from other ERBB family members is necessary for survival and proliferation in KRAS-driven tumors, and that afatinib and neratinib produce an antitumor response.
Selecting therapies for patients with multiple myeloma is challenging because the disease is inherently heterogeneous.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma
Since next-generation sequencing reflex testing has been implemented at Case Western Reserve University School of Medicine, several cases of potentially actionable mutations have been identified that would not have been caught by PCR alone.
Bone imaging is a critical aspect of care for patients with multiple myeloma, and recent advances in imaging modalities have improved detection of lytic lesions and bone marrow involvement—but incorporating these new modalities into clinical practice has been challenging.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
Examining the costs and benefits of repurposing sildenafil as a cancer medication.
Even though cancer drugs only account for approximately 1% of the total health care spend, physicians can serve as advocates for patients struggling to afford recommended treatments.
Q&A With Frank Luh, MD, MS, MHA and Yun Yen, MD, PhD, FACP: Looking to Broaden CMS Coverage for NGS Tests
Restricting use to FDA-approved NGS tests is not an absolute rule that must last forever. But it's a good start, say two physicians.
According to experts, PARP inhibition, radiopharmaceuticals, and immunotherapy could revolutionize how prostate cancer is treated in the coming decade.
An increase in the appearance of colorectal cancer incidence in younger people has prompted the American Cancer Society to revise its current screening guidelines.
Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a meaningful impact on the quality of life for patients as well as treatment costs.
Novel targets in the treatment of melanoma was a hot topic of discussion during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
The heterogeneity of kidney cancer makes each of the tumors unique and treatment decisions based on tumor characteristics especially challenging.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia
- Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia
- Exercise and Cancer
- Increased Body Mass Index May Be Predictive of Recurrence, Progression in Bladder Cancer
- Aspirin, Non-Aspirin NSAID-Use May Improve Survival Outcomes in Ovarian Cancer